News Hub | News Direct

Investing in the $532B Oncology Boom: Key Stocks Shaping the Future of Cancer Treatment

OSTX DAWN GSK ADCT

The global oncology drug market, valued at over $200 billion today, is on pace to reach $532 billion by 2031—a growth story driven not just by rising demand but by genuine innovation. After years of incremental progress, new therapies like antibody-drug conjugates (ADCs) and immunotherapies are making strides against some of oncology's toughest challenges: rare pediatric cancers, relapsed tumors, and diseases like osteosarcoma, where survival rates have barely improved in decades. Regulators are helping accelerate this progress with tools like accelerated approvals and breakthrough designations that are shortening development timelines. At the same time, approaches like comparative oncology—using naturally occurring canine cancers as research models—are providing faster, more clinically relevant data than traditional preclinical studies. This convergence of scientific advancement and commercial opportunity is creating a market that’s evolving faster than ever before. Within this expanding landscape, several companies are at the forefront of pioneering new treatments. Let's take a closer look at how some of the most innovative players in this space are tackling these pressing challenges. OS Therapies (NYSE-A: OSTX) is a clinical-stage biotech company focused on transforming the treatment landscape for osteosarcoma, a rare and aggressive bone cancer that primarily affects children and young adults. The company’s lead drug, OST-HER2, is a novel off-the-shelf immunotherapy that uses a modified form of Listeria bacteria to stimulate the immune system to target and destroy cancer cells that express the HER2 protein. Recent data has further validated the potential of OST-HER2 in treating osteosarcoma. New unpublished research shows that when combined with palliative radiation, OST-HER2 has had a significant impact on dogs with unresected, primary osteosarcoma. Out of 15 dogs treated, 5 experienced survival times exceeding 500 days, with clinical and radiographic arrest of the primary tumor and delayed pulmonary metastases. These findings could have profound implications for the potential use of OST-HER2 as a frontline therapy in humans, potentially before chemotherapy is even considered. This approach could reduce or even eliminate the need for surgery and chemotherapy, offering a more effective and less invasive treatment alternative for patients. This data complements previous research published in the journal Molecular Therapy, which demonstrated how OST-HER2 induces strong immune responses from the very first dose. These responses were shown to correlate with both the prevention of metastasis and long-term survival in dogs that had undergone surgery to remove their primary osteosarcoma. Additionally, the study showed that dogs who initially had weaker immune responses showed significant improvement after the second and third doses, supporting the use of repeated dosing as a potential strategy for treating the disease. The combination of these results marks a critical milestone in OS Therapies' development of OST-HER2. The company is now preparing to submit this new data to the USDA, along with information on their improved manufacturing process, aiming for conditional approval in the United States by 2025. Following this, OS Therapies plans to conduct a pivotal clinical study with the goal of gaining full approval for the treatment by 2026. The company is also on track to secure FDA Accelerated Approval for OST-HER2 in human osteosarcoma, with plans to submit an application by the end of 2025. If approved, OST-HER2 could be one of the first treatments to offer a meaningful improvement in survival for patients with this rare and difficult-to-treat cancer. Moreover, a successful approval would make OS Therapies eligible for a Priority Review Voucher (PRV), which could be sold for a significant financial gain, providing the company with the resources needed to fund future projects. As OS Therapies continues to advance in both human and veterinary applications, its approach to Comparative Oncology is proving to be a game-changer. With a 96% genetic similarity between human and canine osteosarcoma, research in dogs with osteosarcoma offers valuable insights that could accelerate the development of new therapies for humans. OS Therapies is leveraging this unique advantage to not only improve treatments for dogs but also to push the boundaries of cancer treatment in humans. Financially, OS Therapies remains well-positioned for the future. The company raised $12 million in 2024 through an IPO and private placement, and it expects its cash reserves to last through mid-2026. With clinical costs now tapering off as the company moves forward in its regulatory journey, OS Therapies is in a solid position to continue advancing its pipeline without needing to raise additional capital in the near term. The company’s growth isn’t limited to just one drug. Beyond OST-HER2, OS Therapies is also working on an innovative antibody-drug conjugate (ADC) platform, which could allow for custom-designed cancer treatments tailored to various cancers. This growing pipeline positions OS Therapies as a company to watch in the biotech space, offering not only a potential breakthrough in osteosarcoma treatment but also future opportunities in oncology. As the company works toward Accelerated Approval for OST-HER2 by the end of 2025, the potential for significant regulatory milestones, a potential PRV sale, and an expanding clinical pipeline make OS Therapies a standout in the emerging biotech field. Investors, clinicians, and patients alike should keep a close eye on this company as it continues to push forward in the fight against osteosarcoma and other forms of cancer. Day One Biopharmaceuticals (Nasdaq: DAWN) is gaining traction in the pediatric oncology world with OJEMDA (tovorafenib), its lead treatment for children with low-grade glioma (pLGG), a rare brain cancer. OJEMDA is a Type II RAF kinase inhibitor that targets BRAF alterations, which are often found in pLGG patients. It received FDA approval under the accelerated approval pathway, and the early numbers suggest strong adoption—more than 1,600 prescriptions were written in the eight months following its April 2024 launch. Full-year net product revenue came in at $57.2 million, with $29 million in the fourth quarter alone. In late 2024, OJEMDA also earned the “Exclusively Pediatric” designation from CMS, lowering its Medicaid and 340B rebate obligations, which could help margins moving forward. The drug is currently at the center of Day One’s pipeline, with the Phase 3 FIREFLY-2 study ongoing. The company expects to complete enrollment by mid-2026. Beyond OJEMDA, Day One is working to expand its reach in pediatric cancer. DAY301, an antibody-drug conjugate (ADC) targeting PTK7, has cleared its first dosing cohort in a Phase 1a/b trial. If development goes well, it could become a valuable second asset alongside OJEMDA. From a financial standpoint, Day One ended 2024 with $531.7 million in cash and equivalents, giving the company plenty of runway. While the full-year net loss totaled $95.5 million—largely due to R&D and launch costs—the company continues to invest in growth. R&D expenses jumped to $227.7 million in 2024, up from $130.5 million in 2023, driven by the advancement of DAY301 and other pipeline efforts. Even with the losses, Day One is in a strong position: OJEMDA is gaining traction, the pipeline is moving, and the balance sheet is healthy. For anyone watching the space, Day One stands out as a biotech laser-focused on filling a serious treatment gap in pediatric cancer. GSK plc (NYSE: GSK) is making real moves in oncology, especially in tough-to-treat cancers like osteosarcoma. In January, the FDA gave Breakthrough Therapy Designation to one of GSK’s experimental antibody-drug conjugates (ADCs) that targets B7-H3—a protein linked to tumor growth. The drug showed early promise in a mid-stage trial for patients with relapsed or refractory osteosarcoma who’ve already gone through two lines of treatment. That’s a big deal in a space with no currently approved therapies for patients at that stage. Osteosarcoma mostly affects children and young adults, and once it comes back after initial treatment, the outlook gets bleak. GSK’s drug could help fill that gap. The company is now running a global trial aimed at eventually getting the treatment approved more broadly. On the business side, GSK is firing on all cylinders. In February the company launched a $2.5 billion stock buyback after a strong Q4 and raised its long-term revenue forecast. Oncology is now a major focus for GSK’s pipeline, along with respiratory diseases, HIV, and other specialty areas. With five product approvals expected this year—including a relaunch of its blood cancer drug Blenrep—the company looks well-positioned to keep growing in high-need treatment areas. ADC Therapeutics (NYSE: ADCT) stands out as a promising player in the antibody drug conjugate (ADC) space, focusing on the treatment of hematologic malignancies and solid tumors. With a proprietary ADC technology platform, the company is positioning itself to make a significant impact in oncology. Investors looking for growth potential in this innovative field should take note of ADC Therapeutics, particularly with its lead product, ZYNLONTA (loncastuximab tesirine). Recent clinical trial results further solidify the company’s growth trajectory. In December 2024, ADC Therapeutics published updated data from a Phase 2 clinical trial evaluating ZYNLONTA in combination with rituximab for treating relapsed or refractory follicular lymphoma (FL). The results showed a robust 97.4% overall response rate and 76.9% complete response rate, positioning ZYNLONTA as a strong treatment option for high-risk FL patients. These results were published in The Lancet Haematology and presented at the prestigious American Society of Hematology (ASH) Annual Meeting, raising the company’s profile in the oncology field. With progression-free survival remaining strong at 94.6% at 12 months, the long-term potential for ZYNLONTA in treating indolent B-cell lymphomas is clear. Additionally, ADC Therapeutics is making strides with the LOTIS-7 trial, which is evaluating ZYNLONTA in combination with glofitamab for relapsed or refractory diffuse large B-cell lymphoma (DLBCL). The initial data showed impressive results, with a 94% overall response rate and 72% complete response rate, alongside a manageable safety profile. This combination therapy could provide a competitive edge in the highly saturated DLBCL market, demonstrating the potential for ZYNLONTA beyond its initial indication. From a financial perspective, ADC Therapeutics reported stable revenues in Q4 2024, generating $16.4 million in product sales. Despite the flat revenue growth, the company is focused on reducing operating expenses, achieving a 13% year-over-year reduction. With $251 million in cash reserves at the end of 2024, the company is well-positioned to fund operations into the second half of 2026, allowing for continued investment in its clinical pipeline and commercial efforts. For investors, ADC Therapeutics presents a compelling opportunity, particularly as the company progresses through key trials and works towards expanding the indications for ZYNLONTA. Despite the competitive landscape, ADC Therapeutics has demonstrated its ability to deliver results that could appeal to both oncologists and patients, positioning the company for future growth. The promising clinical data, solid cash position, and ongoing commitment to advancing its ADC technology make ADC Therapeutics a stock worth keeping on the radar. Disclaimers: RazorPitch Inc. "RazorPitch" is not operated by a licensed broker, a dealer, or a registered investment adviser. This content is for informational purposes only and is not intended to be investment advice. The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions, or future events or performances are not statements of historical fact and may be forward-looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties that could cause actual results or events to differ materially from those presently anticipated. Forward-looking statements in this action may be identified through the use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements indicating certain actions & quote; may, could, or might occur. Understand there is no guarantee past performance will be indicative of future results. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor's investment may be lost or impaired due to the speculative nature of the companies profiled. RazorPitch has been retained and compensated by OSTX to assist in the production and distribution of this content. RazorPitch is responsible for the production and distribution of this content. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. This content is for informational purposes only; you should not construe any such information or other material as legal, tax, investment, financial, or other advice. Nothing contained in this article constitutes a solicitation, recommendation, endorsement, or offer by RazorPitch or any third-party service provider to buy or sell any securities or other financial instruments. All content in this article is information of a general nature and does not address the circumstances of any particular individual or entity. Nothing in this article constitutes professional and/or financial advice, nor does any information in the article constitute a comprehensive or complete statement of the matters discussed or the law relating thereto. RazorPitch is not a fiduciary by virtue of any persons use of or access to this content. Contact Details RazorPitch Mark McKelvie +1 585-301-7700 mark@razorpitch.com Company Website http://razorpitch.com

April 11, 2025 07:00 AM Eastern Daylight Time

Palatin Technologies Scores Triple Win with Breakthrough Results in Obesity, Colitis, and Kidney Disease

Global Markets News

Completion of Phase 2 Obesity Study With MC4R Bremelanotide Plus GLP-1/GIP Tirzepatide Palatin Announces Positive Phase IIb BREAKOUT Study Results in Patients with Type 2 Diabetic Nephropathy Palatin Announces Completion of Patient Enrollment in Phase 2 Study of Orally Administered Melanocortin Agonist PL8177 in Ulcerative Colitis Palatin Technologies (NYSE American: PTN)* is on a remarkable winning streak, reporting positive clinical results across three major diseases in just the past two weeks. The company's latest victory came today with promising data in diabetic kidney disease presented at the National Kidney Foundation Spring Meeting in Boston. "The positive results from our Phase 2b study evaluating a melanocortin agonist in patients with diabetic Type 2 nephropathy represents our third major clinical milestone across distinct therapeutic areas," said Carl Spana, Ph.D., President and CEO of Palatin. "These results, along with previously announced positive topline data from our Phase 2 obesity and ulcerative colitis studies, and the advancement of our Phase 3 dry eye disease program, demonstrate the breadth and robustness of our melanocortin platform." In the six-month BREAKOUT study, patients with Type 2 diabetic nephropathy showed significant improvements in kidney function after treatment with bremelanotide, a melanocortin agonist. Seventy-one percent of patients achieved meaningful reductions in protein levels in urine and maintained or improved their glomerular filtration rate—both critical markers of kidney health. This latest success caps an impressive series of announcements. On March 31, Palatin reported that its Phase 2 obesity study met its primary endpoint with highly statistically significant results. The co-administered group had a 4.4% reduction in weight compared to 1.6% for the placebo group (p<0.0001). Notably, the company's MC4R agonist appeared to prevent weight regain after tirzepatide discontinuation, potentially addressing one of the biggest challenges in obesity treatment. "This study provides compelling evidence that combining an MC4R agonist with a GLP-1/GIP compound creates a synergistic effect on weight loss," said Jesse Richards, DO, of Oklahoma State University College of Osteopathic Medicine, as quoted in Palatin's press release. "With a critical need for diverse weight loss solutions, this approach offers a promising improvement to GLP-1/GIP monotherapy, particularly for those who struggle with tolerability at high doses." Just days earlier, Palatin announced breakthrough results in ulcerative colitis. Their PL8177 treatment demonstrated clinical response in 78% of treated patients versus 33% on placebo (p<0.005), with clinical remission achieved in 33% of PL8177-treated patients versus 0% on placebo. "We are thrilled with the positive results in this study, especially the meaningful and high rates of achievement for clinical remission and clinical response," Dr. Spana stated in the announcement. "These endpoints align with the FDA's recommended primary and key secondary endpoints for evaluating efficacy in UC clinical trials." The potential market impact of these developments is substantial. Palatin's approach to obesity treatment appears particularly timely as Rhythm Pharmaceuticals just reported successful Phase 3 results for setmelanotide in hypothalamic obesity, showing a -19.8% placebo-adjusted BMI reduction. The two companies represent the only players actively developing MC4R-targeted therapies for obesity conditions. Adding to Palatin's momentum, the FDA recently granted "orphan drug" designation to PL7737, the company's oral melanocortin-4 receptor agonist, for leptin receptor deficiency obesity. This designation provides incentives including tax credits for clinical trials and potential market exclusivity. According to Dr. Spana, the company is advancing discussions with multiple pharmaceutical companies for potential licensing deals. "Several major pharmaceutical companies have shown strong interest in our UC program," he stated in the March 28 press release, "and we believe these positive Phase 2 results in PL8177 treated patients, for the critical efficacy endpoints of both clinical remission and clinical response, could help solidify a potential licensing deal." With multiple clinical successes driving interest in its technology platform across billion-dollar markets including obesity, ulcerative colitis, and kidney disease, Palatin appears to be validating its scientific approach as analysts at H.C. Wainwright maintain a $7 price target on the stock. Recent Palatin Technologies News Highlights: Completion of Phase 2 Obesity Study With MC4R Bremelanotide Plus GLP-1/GIP Tirzepatide Palatin Announces Positive Phase IIb BREAKOUT Study Results in Patients with Type 2 Diabetic Nephropathy Palatin Announces Completion of Patient Enrollment in Phase 2 Study of Orally Administered Melanocortin Agonist PL8177 in Ulcerative Colitis *DISCLAIMER: This alert is published by Wall Street Wire. Wall Street Wire does not provide financial or investment advice, and our content does not represent an offer to buy or sell securities. Wall Street Wire is a promotional content brand and its operators are not registered brokers, dealers, or investment advisers. This alert contains and is a form of paid promotional content for to Palatin Technologies and was produced as part of their paid subscription to Wall Street Wire’s distribution and promotional content services. This alert has not been reviewed or approved by Palatin Technologies prior to publication. Please review the full disclaimers and compensation disclosures here: redditwire.com/terms Contact Details WALL STREET WIRE | NEWS News Coverage media.globalmarkets@gmail.com

April 10, 2025 08:37 AM Eastern Daylight Time

Investing in Oncology: 4 Companies Driving Cancer Treatment Innovation

OSTX DAWN CADL YMAB

The oncology sector in the U.S. is on the verge of a transformative breakthrough. With the cancer therapeutics market already valued at over $170 billion in 2024 and expected to exceed $500 billion by 2034, the industry is experiencing a surge of innovation driven by cutting-edge treatments like immunotherapies and targeted therapies. As cancer rates continue to rise, particularly among children and underserved populations, the urgency for novel solutions has never been greater. Investors are increasingly drawn to this rapidly evolving field, where new therapies are not just improving survival rates but offering hope where there was none. With breakthroughs happening at an unprecedented pace, the oncology space presents an exciting and compelling opportunity for those looking to invest in the future of healthcare. Now, let’s take a look at a few promising stocks in this expanding sector that could be worth keeping an eye on. OS Therapies (NYSE-A: OSTX) is a clinical-stage biotech company that’s aiming to make a real difference in one of the toughest areas of medicine—osteosarcoma, a rare and aggressive bone cancer that mostly affects children and young adults. Their lead drug, OST-HER2, is not your typical cancer treatment. It's an off-the-shelf immunotherapy that uses a modified form of Listeria bacteria to kickstart the body’s immune system into attacking cancer cells that express the HER2 protein. So far, the results have been very promising. In a Phase 2b clinical trial involving 39 patients with recurrent osteosarcoma that had spread to the lungs but was surgically removed, OST-HER2 showed a statistically significant boost in 12-month event-free survival—33% compared to 20% in similar patients who didn’t receive the treatment (p=0.0158). That’s a big deal in a cancer type where survival rates haven’t improved much in decades. "We believe OST-HER2 will make a significant difference in the treatment of osteosarcoma and welcome the opportunity to engage with FDA to get this investigational treatment to patients as quickly as possible,” said Paul Romness, CEO of OS Therapies. And the company is moving fast. OST-HER2 has already received special FDA and European designations, including: Rare Pediatric Disease Designation (RPDD) Fast Track Designation Orphan Drug Designation in both the U.S. and Europe These help speed up the development and review process. OS Therapies is now preparing to submit a Biologics License Application (BLA) to the FDA by late 2025, with the hope of receiving Accelerated Approval shortly after. In fact, the company recently requested a formal meeting with the FDA to agree on surrogate endpoints—essentially the key data the agency wants to see—in support of Breakthrough Therapy Designation and Accelerated Approval. That meeting is expected to happen in Q2 2025, and if all goes well, OST-HER2 could be approved by year-end. “We are excited to meet with the FDA... The goal is receiving Accelerated Approval for OST-HER2 by year-end 2025,” said Dr. Robert Petit, OS Therapies’ Chief Medical & Scientific Officer. There’s also potential upside beyond approval. If the drug is greenlit before September 30, 2026, OS Therapies is eligible for a Priority Review Voucher (PRV)—a valuable incentive from the FDA that the company could sell. A recent PRV sold for $150 million in February 2025, and that kind of windfall could help OS Therapies fund its next programs without needing to raise more money. OST-HER2 isn’t just being tested in people—it’s also been conditionally approved by the USDA for treating osteosarcoma in dogs, which naturally develop the disease in much the same way as humans. Dogs with cancer have been shown to respond to OST-HER2, and researchers are using this data to better understand which biomarkers might predict a strong response in people. Why does this matter? Because human and canine osteosarcoma share 96% genetic similarity. This growing field of Comparative Oncology is giving scientists like those at OS Therapies a unique window into how these therapies might work even before full human trials are complete. The treatment—and its story—will even be featured in the upcoming PBS documentary “Shelter Me: The Cancer Pioneers.” OST-HER2 is just the beginning. OS Therapies is also developing a next-generation Antibody Drug Conjugate (ADC) platform with tunable payloads—meaning they can design custom treatments for different cancers. This ADC program could offer future partnering or licensing opportunities, helping diversify the company’s pipeline. Financially, OS Therapies appears solid. The company completed both an IPO and private placement in 2024, raising $12 million and projecting enough cash to operate through mid-2026. With the heaviest clinical costs now behind them, OS Therapies expects lower spending moving forward. “We expect a significantly reduced outlay beginning in the second quarter of 2025,” said Chris Acevedo, CFO of OS Therapies. “We have reduced our burn rate substantially... and expect cash on hand to last into 2026.” Investors interested in emerging biotech should keep a close eye on OS Therapies (OSTX). With: Strong Phase 2b results Imminent regulatory milestones High-value PRV opportunity A unique canine-human comparative oncology angle A growing immunotherapy and ADC pipeline OSTX could be on the verge of something big. If OST-HER2 wins approval in late 2025, not only could it bring hope to children and families fighting this devastating disease, but it might also mark a major inflection point for the company’s valuation and visibility in the biotech space. Candel Therapeutics, Inc. (Nasdaq: CADL) is a clinical-stage biopharmaceutical company that focuses on developing off-the-shelf multimodal biological immunotherapies for cancer treatment. The company’s approach includes two distinct immunotherapy platforms: one using genetically modified adenovirus (CAN-2409) and the other using herpes simplex virus (CAN-3110). CAN-2409 is currently being tested in phase 2a clinical trials for non-small cell lung cancer (NSCLC), and it has completed phase 2a and phase 3 trials in pancreatic cancer and localized prostate cancer, respectively. Meanwhile, CAN-3110, from the herpes simplex virus platform, is undergoing a phase 1b clinical trial in recurrent high-grade glioma (rHGG). Candel also employs its enLIGHTEN Discovery Platform to identify new viral immunotherapies for solid tumors. In December 2024, Candel announced positive final survival data from a phase 2a clinical trial involving patients with borderline resectable pancreatic ductal adenocarcinoma (PDAC). Patients treated with CAN-2409 alongside standard care experienced a significant median overall survival benefit of 31.4 months, compared to just 12.5 months in the control group. The data indicated that long-term survivors in the treatment group had a substantially better survival rate, even in metastatic disease, highlighting the sustained benefits of CAN-2409. This promising data led the FDA to grant both fast-track and orphan drug designations for CAN-2409 in pancreatic cancer. The company also revealed positive results from its phase 3 clinical trial of CAN-2409 in prostate cancer in December 2024. In this trial, CAN-2409, combined with standard radiation therapy, resulted in a 30% reduction in the risk of recurrence or death compared to the control group. In addition, the treatment arm demonstrated an 80.4% pathological complete response rate in post-treatment biopsies, compared to 63.6% in the control group. These findings are seen as a significant step toward regulatory approval for CAN-2409 in the treatment of localized prostate cancer, and the study was conducted under a Special Protocol Assessment (SPA) with the FDA. Candel also provided an update on its phase 1b trial of CAN-3110 in recurrent high-grade glioma (rHGG). Data presented at the 6th Annual International Oncolytic Virotherapy Conference in October 2024 showed promising early survival outcomes, with three out of six patients surviving for over a year following repeated doses of CAN-3110. The company received both fast-track and orphan drug designations from the FDA for CAN-3110 in rHGG. Furthermore, Candel entered into a strategic partnership with IDEA Pharma, a biopharmaceutical strategy consultancy, in 2024. This collaboration will provide commercial insights into the development and commercialization of CAN-2409. Additionally, Dr. Elizabeth M. Jaffee, a leading pancreatic cancer expert, joined the company’s Research Advisory Board, enhancing its focus on advancing treatments for pancreatic cancer. In April 2025, Candel published the results of a phase 1b trial exploring the combination of CAN-2409 with nivolumab and standard care in newly diagnosed high-grade glioma patients. The data showed that the combination was well tolerated and resulted in extended survival for a subset of patients. A notable finding was the increase in T cell receptor (TCR) density and diversity, which correlated with improved survival outcomes. This reinforces the potential of CAN-2409 as a treatment for a wide range of solid tumors. Financially, Candel reported research and development expenses of $4.8 million for the fourth quarter of 2024, down from $7.3 million the previous year. General and administrative expenses increased slightly to $3.3 million for the quarter. The company posted a net loss of $14.1 million for the quarter, compared to a net loss of $11.1 million in the same period the previous year. For the full year 2024, Candel’s net loss amounted to $55.2 million, up from $37.9 million in 2023. As of December 31, 2024, the company had $102.7 million in cash and equivalents, which is expected to fund its operations into the first quarter of 2027. Y-mAbs Therapeutics, Inc. (Nasdaq: YMAB) is a biopharmaceutical company that is making significant strides in the fight against pediatric cancer, particularly high-risk neuroblastoma. Neuroblastoma is a rare and aggressive cancer that mainly affects children, and Y-mAbs is dedicated to improving the outcomes for patients who are facing this challenging disease. The company has developed DANYELZA (naxitamab), the first FDA-approved treatment for patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow. This breakthrough treatment offers hope to children who have exhausted other therapy options. One of the most promising aspects of Y-mAbs is its work with naxitamab, a treatment that has shown strong efficacy in clinical trials. According to a Phase 2 clinical trial published in Nature Communications, naxitamab demonstrated a 50% overall response rate (ORR) among patients with relapsed or refractory high-risk neuroblastoma. Notably, the therapy showed particularly strong results in targeting residual disease in the bone and bone marrow, which are common areas where cancer cells hide and resist traditional chemotherapy. Naxitamab is an anti-GD2 monoclonal antibody, meaning it targets the GD2 molecule found on the surface of neuroblastoma cells. This therapy is combined with granulocyte-macrophage colony-stimulating factor (GM-CSF), a substance that boosts the immune system to fight cancer. In clinical trials, naxitamab has shown manageable safety and promising efficacy, with many patients achieving a partial or complete response. In fact, 58% of patients with bone disease saw a positive response, making it an essential option for those who haven’t responded to other treatments. Y-mAbs has been actively working to expand the reach of DANYELZA globally. In 2024, the company reported significant revenue growth from its international markets, particularly in Europe and Asia. With DANYELZA now available in 69 U.S. centers and expanding into new regions, the company is well-positioned to bring this life-saving treatment to more children in need. As of early 2025, Y-mAbs has adjusted its business strategy to focus on expanding the clinical development of its Radiopharmaceuticals Platform, alongside continuing to drive the growth of DANYELZA. The company has a robust pipeline, including its innovative SADA PRIT technology, which could open up new avenues for treating solid tumors in pediatric cancer patients. Despite a net loss in 2024, Y-mAbs is focusing on cost efficiency and capital investment to fuel future growth. With a strong balance sheet and clear plans to expand its clinical and commercial efforts, Y-mAbs could offer significant upside potential for investors interested in the growing field of pediatric cancer therapeutics. For investors looking to support innovative treatments in pediatric cancer, Y-mAbs Therapeutics presents a unique opportunity, with a solid product, promising clinical data, and an evolving strategy for growth. Day One Biopharmaceuticals, Inc. (Nasdaq: DAWN ) is making significant strides in pediatric cancer treatment, tackling one of the most critical areas of unmet need in the oncology space. The company’s lead drug, OJEMDA (tovorafenib), is a promising targeted therapy designed to treat pediatric low-grade glioma (pLGG), a rare brain tumor that predominantly affects children. OJEMDA is a Type II RAF kinase inhibitor, targeting BRAF mutations that are common in pLGG. Approved by the FDA under accelerated approval, the treatment is a breakthrough in a field where treatment options have been limited. Since its launch in April 2024, OJEMDA has shown strong sales, with net product revenues of $57.2 million for the full year. In the first eight months post-launch, over 1,600 prescriptions were written, highlighting the demand for new therapies in this space. Day One has positioned OJEMDA as a cornerstone of its pipeline, and the company is already advancing its clinical strategy with a global, pivotal Phase 3 trial called FIREFLY-2. Full enrollment in the trial is expected by the first half of 2026, which could pave the way for further regulatory progress. Additionally, OJEMDA received Exclusively Pediatric designation from the Centers for Medicare & Medicaid Services in late 2024, which is expected to reduce the rebate percentage for the drug, further supporting its commercial viability. The company’s financial outlook appears solid, with a year-end 2024 cash balance of $531.7 million, providing a strong runway for future growth. Day One is also making progress in other areas, including its development of DAY301, a targeted antibody-drug conjugate (ADC), which has entered early-stage clinical trials. If successful, DAY301 could add to Day One’s growing pipeline and diversify its offerings in the pediatric oncology market. While Day One recorded a net loss in 2024, the company’s focus on expanding access to OJEMDA and advancing its pipeline positions it well for long-term success. For investors, Day One represents a unique opportunity to support innovation in pediatric cancer therapeutics, with a promising product, a strong pipeline, and a dedicated team pushing the boundaries of what’s possible in cancer treatment. Disclaimers: RazorPitch Inc. "RazorPitch" is not operated by a licensed broker, a dealer, or a registered investment adviser. This content is for informational purposes only and is not intended to be investment advice. The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions, or future events or performances are not statements of historical fact and may be forward-looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties that could cause actual results or events to differ materially from those presently anticipated. Forward-looking statements in this action may be identified through the use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements indicating certain actions & quote; may, could, or might occur. Understand there is no guarantee past performance will be indicative of future results. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor's investment may be lost or impaired due to the speculative nature of the companies profiled. RazorPitch has been retained and compensated by OSTX to assist in the production and distribution of this content. RazorPitch is responsible for the production and distribution of this content. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. This content is for informational purposes only; you should not construe any such information or other material as legal, tax, investment, financial, or other advice. Nothing contained in this article constitutes a solicitation, recommendation, endorsement, or offer by RazorPitch or any third-party service provider to buy or sell any securities or other financial instruments. All content in this article is information of a general nature and does not address the circumstances of any particular individual or entity. Nothing in this article constitutes professional and/or financial advice, nor does any information in the article constitute a comprehensive or complete statement of the matters discussed or the law relating thereto. RazorPitch is not a fiduciary by virtue of any persons use of or access to this content. Contact Details RazorPitch Mark McKelvie +1 585-301-7700 mark@razorpitch.com Company Website http://razorpitch.com

April 09, 2025 07:00 AM Eastern Daylight Time

Aloe Semiconductor demonstrates 850-Gb/s DP-BIDI-PAM4 OSFP module at OFC 2025

Aloe Semiconductor

Aloe Semiconductor, Inc. will demonstrate 850-Gb/s per fiber pair at the Optical Fiber Communication (OFC) Conference and Exhibition in San Francisco, CA the week of March 31, 2025. This showcases the first ever practical combination of dual polarization with bi-directional technology (DP-BiDi-PAM4) to achieve a factor of four increase in fiber capacity for short links. DP and BiDi technology each increase optical escape and cabling density by a factor of two, for a total factor of four when used together. Optical escape and cabling density are becoming significant limitations in scale out and eventually scale up, making the combination of DP and BiDi use an important innovation. This technology also benefits optical circuit switching (OCS), which has been proven to significantly reduce cost and power. “We are committed to making DP-PAM4 practical, and we are excited to show our progress,” said Aloe’s CEO Christopher (Chris) Doerr. “We also show how polarization multiplexing is an orthogonal dimension and can be combined with other density-improvement technologies, such as BiDi. In the future, adding 200-Gbaud technology, 1.6T per fiber pair using DP-BiDi PAM4 will be conceivable.” The module block diagram for this demonstration is shown below. The BiDi uses 1271 nm to transmit in one direction and 1311 nm in the other. The Aloe single-chip silicon-photonic integrated circuit (PIC) contains both the transmitter and receiver. The PICs are flip-chipped together with the Broadcom Sian 2 digital-signal processor DSP and put in an Eoptolink module. The modulators are driven with the internal drivers of Sian. A transimpedance amplifier (TIA) IC is used to amplify the high-speed photo-detected signals. "We believe DP-PAM4 is an innovative technology to further increase short reach fiber capacity without the need for new silicon to support 1.6T," said Dirk Lutz, Engineer at Eoptolink. "We are excited to collaborate with Aloe in this new exciting technology." With this demonstration, Aloe continues to pave the way to higher speeds, opening up a path to 1.6T speeds on short-reach fiber links. DP demonstrations will be running at the Eoptolink booth and Aloe’s room 1018 in the Corporate Village and require a reservation to attend. Please contact Chris at cdoerr@aloesemi.com for more details. Aloe Semiconductor was founded in 2022 by former Acacia Communications Associate Vice President of Advanced Development Christopher Doerr and is based in New Jersey, USA. Find out more about the company here: https://aloesemi.com/. About Aloe Semiconductor, Inc. Aloe Semiconductor, Inc. (Aloe) is a semiconductor design company that provides best-in-class photonic integrated circuits using silicon photonics technology for optical communications. Founded in 2022, Aloe Semiconductor is creating industry-leading, high performance,application-specific silicon photonics and electronics solutions, helping networks to scale from 212G to 425G and 850G using ground-breaking dual-polarization technology. Contact Details Wilkinson + Associates Mrs Leah F Wilkinson +1 703-907-0010 leah@wilkinson.associates Company Website https://aloesemi.com/

April 01, 2025 02:30 PM Eastern Daylight Time

Aloe Semiconductor showcases 160-Gbaud PAM4 from a silicon-photonic modulator at OFC 2025

Aloe Semiconductor

Aloe Semiconductor, Inc. will showcase a 160-Gbaud PAM4 (320-Gb/s) from a silicon-photonic (SiPh) modulator at the Optical Fiber Communication (OFC) conference in San Francisco, CA the week of March 31, 2025. Aloe Semiconductor’s innovative design allows silicon photonics to reach the next jump in bit rate per lane without having to add non-CMOS materials, such as LiNbO 3, polymer, gold, or III-V elements. In optical input/output (OIO) and co-packaged optics (CPO), advanced silicon packaging plays a large role, and continuing to use pure silicon for the photonics, instead of adding new materials, will shorten the time to market. Aloe’s new design will be especially important for these applications, allowing for high speeds at low cost. “We show that with innovative design, silicon photonic modulators can move well beyond 106 Gbaud, allowing the next generation to continue taking advantage of silicon’s integration capability, advanced packaging compatibility, and fast time to market,” said Aloe’s CEO Christopher (Chris) Doerr. The enabling technology is a novel SiPh Mach-Zehnder modulator (MZM) design that increases bandwidth without trade-offs in loss or required voltage drive. It requires only conventional silicon processing, saving power and cost. In this demonstration, the modulator is driven by a high-bandwidth open-collector driver from MACOM. The driver and modulator are flip-chipped side-by-side on a high-density substrate. The electrical input signal is generated by a Keysight AWG 8199B and the optical signal is received by a Keysight 1032A. The 160-Gbaud PAM4 eye diagram is shown below. With this demonstration, Aloe continues to pave the way to higher speeds, using silicon photonics technology to create radically new, application-specific solutions for optical communications. The demonstration is running at MACOM booth #2028. Please contact Chris at cdoerr@aloesemi.com for more details. Aloe Semiconductor was founded in 2022 by former Acacia Communications Associate Vice President of Advanced Development Christopher Doerr and is based in New Jersey, USA. Find out more about the company here: https://aloesemi.com/. About Aloe Semiconductor, Inc. Aloe Semiconductor, Inc. (Aloe) is a semiconductor design company that provides best-in-class photonic integrated circuits using silicon photonics technology for optical communications. Founded in 2022, Aloe Semiconductor is creating industry-leading, high performance,application-specific silicon photonics and electronics solutions, helping networks to scale from 212G to 425G and 850G using ground-breaking dual-polarization technology. Contact Details Wilkinson + Associates Mrs Leah F Wilkinson +1 703-907-0010 leah@wilkinson.associates Company Website https://aloesemi.com/

April 01, 2025 02:22 PM Eastern Daylight Time

Introducing ELSA-16: Casela Technologies Powers the Future of AI I/O with Breakthrough 16 Channel External Laser Source Platform Architectures

Casela Technologies

Casela Technologies (Casela), a leading innovator in high-power semiconductor laser solutions, today announced the launch of ELSA-16, a next-generation, pluggable 16-channel External Laser Source (ELS) platform designed to unlock new levels of performance, flexibility, and scalability in Co-Packaged Optics (CPO) and silicon photonics-based systems powering AI workloads. Engineered for the rapidly evolving demands of AI infrastructure, the ELSA-16 integrates 16 high-power Distributed Feedback (DFB) lasers with advanced control electronics in a compact, thermally optimized form factor. With optional TEC (Thermoelectric Cooler) integration for enhanced wavelength stability, the platform is fully customizable to target specific power, wavelength, and efficiency requirements. ELSA-16 modules utilize polarization-maintaining (PM) fiber outputs and an OSFP electrical interface with CMIS-based firmware for seamless integration. “The ELSA-16 represents a quantum leap in flexible and scalable external laser sources,” said Milind Gokhale, Co-Founder and CTO of Casela. “From powering high-bandwidth chiplet I/O to enabling dense wavelength division multiplexing, ELSA-16 is the ideal solution for next-generation optical networks.” Key features of the ELSA-16 platform include: Customizable Power Profiles: Supports Casela’s 200–300 mW class lasers with fiber-coupled output powers ranging from 150–200 mW per channel. Broad Wavelength Support: Available in 1310nm and CWDM-4 options for DR/FR links, and CW-WDM/DWDM variants for ring-based silicon modulators. Comb Source Capability: Enables up to 128 optical channels via 16 x 8-comb source configurations, with >12mW per wavelength per fiber on a 200 GHz grid. DWDM Scalability: Future-ready for tighter wavelength spacing and dynamic control to support evolving CPO architectures. At OFC 2025, Casela will showcase a 16-wavelength version of ELSA-16, each powering dense comb sources to demonstrate the platform’s potential to support 128+ channels in a compact, pluggable form—redefining the limits of scalability in AI and HPC systems. Visit the company in meeting room 6549 to preview Casela’s entire ELSA-16 product family. On Sunday, March 30, Casela’s CTO Milind Gokhale joined a panel of industry leaders during the “ High Power and Multi-Wavelength Laser Light Sources ” workshop at OFC 2025. In a forward-looking discussion, the group explored how innovation in laser architecture, integration and performance will drive the next generation of optical interconnects for AI/ML. Topics included multi-wavelength roadmaps, serial and parallel interface demands, high-efficiency packaging and the scalability required for future systems. As AI and high-performance computing continue to demand ultra-efficient and high-bandwidth I/O, Casela’s ELSA-16 platform delivers industry-leading wall plug efficiency, precise wavelength control, and unparalleled scalability. With support for high-density, parallel optical links, ELSA-16 offers a clear path toward more compact, power-efficient, and cost-effective optical interconnects at the silicon level. About Casela Technologies: Casela is a pioneer in high-power semiconductor laser design, delivering cutting-edge laser solutions for data center, AI, and telecom applications. With deep expertise in silicon photonics and optical integration, Casela’s mission is to accelerate the future of optical interconnects through innovation, performance, and scalability. For more information, www.caselatech.com Contact Details Wilkinson + Associates Leah Wilkinson +1 703-907-0010 leah@wilkinson.associates Company Website https://www.caselatech.com/

March 31, 2025 08:35 AM Pacific Daylight Time

Image

Market Alert: Palatin's Disruptive Obesity Drug Combination Shows Groundbreaking Weight Loss Results in Phase 2 Topline Data (NYSE: PTN)

Global Markets News

Palatin Technologies* has unveiled compelling topline results from its Phase 2 study showing that patients receiving its obesity drug bremelanotide in combination with tirzepatide achieved a 4.4% weight reduction compared to just 1.6% for placebo—a highly statistically significant difference (p<0.0001). The eight-week trial demonstrated that combining these two mechanisms creates a synergistic effect, with 40% of patients in the combination group achieving at least 5% weight loss compared to 27% with tirzepatide alone. The economic potential of anti-obesity drugs is enormous, with the market expected to reach US$100 billion by 2030. As obesity rates continue to climb globally, with the number of obese individuals worldwide projected to increase from 980 million to nearly 2 billion from 2022 to 2035, innovative treatment approaches like Palatin's are positioning themselves in this rapidly expanding market. Perhaps most intriguing for the obesity treatment landscape, Palatin's data revealed that its drug effectively halted the rapid weight regain typically seen after stopping GLP-1/GIP therapy. This addresses one of the most significant challenges facing current obesity treatments, where patients often regain substantial weight after discontinuation. The economic potential of anti-obesity drugs is enormous, with the market expected to reach US$100 billion by 2030. As obesity rates continue to climb globally, with the number of obese individuals worldwide projected to increase from 980 million to nearly 2 billion from 2022 to 2035, innovative treatment approaches like Palatin's are positioning themselves in this rapidly expanding market. Palatin is advancing development of next-generation long-acting injectable and oral versions of its obesity compounds, with investigational new drug applications planned for late 2025 and clinical data expected in early 2026. The company is one of just two developing therapies targeting this specific biological pathway for obesity. This announcement follows recent positive news from Palatin's ulcerative colitis program and FDA orphan drug designation for its oral obesity compound for rare genetic obesity disorders, demonstrating the company's momentum across multiple therapeutic areas with significant unmet needs. Subscribe For More Alerts: https://newsletter.page/wallstreetalerts Recent Palatin Technologies News Highlights: Palatin Announces Positive Topline Results from Phase 2 Ulcerative Colitis (UC) Study of Oral Melanocortin-1 Receptor Agonist PL8177 Completion of Phase 2 Obesity Study With MC4R Bremelanotide Plus GLP-1/GIP Tirzepatide Palatin Announces Positive Phase IIb BREAKOUT Study Results in Patients with Type 2 Diabetic Nephropathy Palatin Announces Completion of Patient Enrollment in Phase 2 Study of Orally Administered Melanocortin Agonist PL8177 in Ulcerative Colitis *DISCLAIMER: This alert is published by Wall Street Wire. Wall Street Wire does not provide financial or investment advice, and our content does not represent an offer to buy or sell securities. Wall Street Wire is a promotional content brand and its operators are not registered brokers, dealers, or investment advisers. This alert contains and is a form of paid promotional content for to Palatin Technologies and was produced as part of their paid subscription to Wall Street Wire’s distribution and promotional content services. This alert has not been reviewed or approved by Palatin Technologies prior to publication. Please review the full disclaimers and compensation disclosures here: redditwire.com/terms Contact Details Wall Street Wire Market Aerts Desk media.globalmarkets@gmail.com

March 31, 2025 09:19 AM Eastern Daylight Time

Benestar Brands and Palmex Alimentos are now the new Monarca Authentic Snacks Company: Leading Hispanic Snacking in the Americas

Monarca Authentic Snacks

Benestar Brands (formerly Evans Food Group Ltd.) and Palmex Alimentos, S.A. de C.V. (“Palmex”) proudly unveiled their new unified brand identity: Monarca Authentic Snacks, which becomes the new premier leader in Hispanic snacking across the Americas. This milestone builds on the successful December 2023 merger of the two companies, transforming two respected industry names into a new category leader of Hispanic and Hispanic-inspired snacks, with authentic flavors and high-profile innovation that positions the company for accelerated growth in the Hispanic snacking category across North, Central, and South America. As a vertically integrated manufacturer of crispy snacks, pork rinds, tortilla chips, snack mixes and in-pack salsa solutions, Monarca Authentic Snacks is a powerhouse of consumer brands as well as a leading partner to snack manufacturers and retailers across the Americas, with the highest quality standards. With nine manufacturing plants in the U.S. and Mexico and distribution in over 17 countries, the company is uniquely positioned to lead the industry, leveraging over 90 years of heritage and commitment to excellence. A Vision for Growth and Leadership “Our ambition is to be the leading and fastest-growing crispy snacks company in the hemisphere,” said Jose Luis Prado, Chairman and CEO of Monarca Authentic Snacks. “For nearly a century, we have crafted pellets and snacks with delicious, authentic Hispanic flavors. With this new identity, we are not just embracing our legacy—we are positioning ourselves for the future. The Hispanic segment is the fastest growing in the U.S. and 75% of U.S. consumers are actively looking for new and unique flavors, reinforcing our strategy to lead and expand the market.” The Inspiration Behind Monarca Authentic Snacks “The launch of Monarca Authentic Snacks harnesses the combined strength of Benestar / Evans and Palmex under a singular identity inspired by the Monarch butterfly—a powerful symbol whose remarkable migration from Central Mexico to Canada, mirrors the company's path, embodying the heritage, resilience, and transformation that drive its vision forward,” said Jesus Velazquez, U.S. President, Monarca Authentic Snacks. Heritage –The Monarch butterflies’ migration from Mexico to the U.S. and Canada spans generations, always returning to its origins. Similarly, its brand stays rooted in tradition while looking to the future. Resilience –Throughout more than 90 years navigating market fluctuations and industry challenges, Monarca Authentic Snacks has demonstrated the same resilience as the Monarch butterfly, consistently emerging stronger after each challenge. Transformation –Just as the Monarch butterfly undergoes metamorphosis, Monarca Authentic Snacks has evolved through strategic mergers and acquisitions to expand its reach and capabilities. Transcendence –Just as Monarch butterflies possess extraordinary navigational abilities to reach their destination, Monarca Authentic Snacks maintains unwavering focus on its goal to become the premier and fastest-growing crispy snacks enterprise throughout the Americas. Community –Monarch butterflies contribute significantly to ecological well-being through pollination; similarly, Monarca Authentic Snacks demonstrates commitment to strengthening the communities it serves and the environment of the Monarch butterfly. A Powerhouse in Hispanic Snacking Monarca Authentic Snacks brings together a diverse and powerful portfolio of consumer and B2B brands, including: Mac’s – The #1 Pork Rind Brand in the U.S. 4505 – The #1 Premium Pork Rind Brand in the U.S. Turkey Creek – The #3 Pork Rind Brand in Convenience stores in the U.S. Chicas – The #2 fastest growing Premium Corn Tortilla Chip among Top Selling Brands in the U.S. Cazo de Oro – The fastest-growing Tortilla chips with authentic Mexican-recipe and Hispanic branded Pork Rinds and Bulk Las Ricas – The new leading brand for Hispanic-inspired “Street Snacks” Evans – A leading pork rind pellet ingredient brand Palmex – A leading crispy snacks pellet ingredient brand Source: Circana Unify+ - Mulo+ w/Conv L52wks ending 2/23/25 Delivering Value Through Innovation and Scale Monarca Authentic Snacks stands at the forefront of the Hispanic snacking market, offering unparalleled innovation capabilities, expanded production capacity, and deep category expertise. By combining the strengths of Benestar / Evans and Palmex, the company is uniquely positioned to drive exciting new snacking concepts, strategic partnerships, and meet the evolving needs of consumers and retailers alike. About Monarca Authentic Snacks Monarca Authentic Snacks is the premier Hispanic snack company in the Americas, dedicated to delivering bold, authentic flavors through crispy snacks, pork rinds, and tortilla chips. With a legacy spanning 90 years, Monarca Authentic Snacks continues to inspire and bring joy to consumers across the hemisphere. For more information, visit www.monarcasnacks.com. About Wind Point Partners Founded in 1984, Wind Point Partners is a Chicago-based private equity investment firm with approximately $6 billion in assets under management. The firm’s Vision, Talent, Transformation (“VTT”) investment strategy focuses on partnering with top caliber management teams around a clear and exciting plan to invest behind a business to achieve transformational growth and value creation. The firm’s Executive Advisor Partner (“EAP”) network is comprised of more than 40 high-caliber executives who are closely aligned with Wind Point and contribute across all aspects of the firm’s investment process. Wind Point targets well-positioned middle market businesses within the business services, consumer products and industrial products industries. Since inception, Wind Point has deployed ten private equity buyout funds in partnership with highly-regarded institutional investors around the world, including public pensions, insurance companies, endowments, foundations, fund of funds and family offices. Additional information about Wind Point is available at www.windpointpartners.com. About Highlander Partners Highlander Partners, L.P. is a Dallas-based private investment firm with more than $3 billion in assets under management. The firm focuses on making investments in businesses in targeted industries where the principals have significant operating and investing experience. Highlander employs a buy and build investment approach, creating value by helping companies grow both organically and through acquisitions. For more information, visit www.highlander-partners.com. Contact Details Monarca Authentic Snacks Michelle Suhrie +1 800-543-7113 Michelle.Suhrie@MonarcaSnacks.com

March 28, 2025 09:00 AM Eastern Daylight Time

DUE TO THE DECISION OF THE TAX AUTHORITIES NOT TO REFUND VAT, FERREXPO WARNS OF SERIOUS NEGATIVE CONSEQUENCES: REDUCTION IN WORKFORCE, PROCUREMENT, TAXES, AND INVESTMENT

Ferrexpo

Ferrexpo, an iron ore company headquartered in Switzerland and listed on the London Stock Exchange, warns about the negative socio-economic consequences of the decision of the Ukrainian tax authorities to suspend VAT refunds for January 2025 in the amount of UAH 512.9 million (approximately US$12.5 million). The suspension of VAT refunds puts additional financial pressure on Ferrexpo. This means that the company will be forced to reduce production and sales. These actions cause damage and further complicate already difficult operating conditions. Without VAT refunds, Ferrexpo is forced to radically reduce the scale of its business to only 25% of its full production capacity. This has an immediate impact, since planned production will be cancelled, resulting in the following consequences: 1. Thousands of jobs will be at risk; 2. Tax revenues to the Poltava region and the state budget of Ukraine will immediately decrease by at least 50%; 3. Ferrexpo will be forced to stop any future investments in Ukraine; 4. Purchases of goods and services in Ukraine will be halved, which will put local and national companies that depend on Ferrexpo at risk. This also includes reducing the use of Ukrainian railways and ports; 5. The economic and social stability of local communities will be disrupted. Commenting on the economic and social risks, Lucio Genovese, Executive Chairman, said: "Ferrexpo is an important contributor to Ukraine's economy and society, especially in times of war. A monthly VAT refund is a significant cash flow contribution for any company, and if it is not received, will have a huge impact on the business and all its stakeholders. Ferrexpo calls on the Ministry of Finance and the State Tax Service of Ukraine to take urgent and effective measures to restore VAT refunds." Chief Operating Officer and Head of the Board of Ferrexpo Poltava Mining, Viktor Lotous, added: “Horishni Plavni, the city that was built around our operations, is home to more than 50,000 people, including more than 8,000 internally displaced people. In one way or another, every household in Horishni Plavni and the surrounding area is dependent on the activities of Ferrexpo Poltava Mining. By extension we are also a critical contributor to the greater Poltava region and indeed to Ukraine. Our employees, unions, and community leaders, are nervous about the viability of our enterprise, their livelihoods, and the community.” Information on the decisions of the Ukrainian tax authorities In the notification, the tax authorities note that the suspension of VAT refunds is associated with the introduction of personal sanctions against Kostiantyn Zhevago. As previously announced, these sanctions are personal to Mr. Zhevago and have not been imposed directly on the company. Ferrexpo believes that personal sanctions against Konstantin Zhevago should not be used to put financial pressure on the company, especially when the majority of Ferrexpo's voting shares are owned by international investors, including some of the largest global banks, investment, pension, and sovereign wealth funds. Last week, Ferrexpo announced a write-down of the value of its operating assets in the amount of US$72 million due to a decrease in projected cash flows. The company suffered a loss of US$50 million in 2024 due to higher costs and lower prices for its products. Ferrexpo is one of the largest industrial companies in Ukraine and an important foundation of the local, regional, and national economy. This contribution is more significant in wartime conditions. Since the beginning of Russia's full-scale invasion of Ukraine, Ferrexpo has made a significant contribution to Ukraine's economy worth more than US$2 billion, including: 1. Continuing to work with a full workforce of over 8,000 people, paying more than US$150 million in salaries. 2. As a major buyer of goods and services in Ukraine, paying suppliers more than US$1.8 billion. 3. Supporting the Government of Ukraine, paying more than US$300 million in taxes and royalties. 4. Investing more than US$300 million in capital expenditures to support and modernise mining and processing operations. Ferrexpo calls on the Ministry of Finance and the State Tax Service of Ukraine to take urgent and effective measures to restore VAT refunds and not jeopardize people's livelihoods, fiscal and social contributions during this critical period inthe history of Ukraine. Instead of forcing Ferrexpo to reduce its business, the authorities should promote its growth so that the company can further support the Ukrainian economy. Ferrexpo is an iron ore company headquartered in Switzerland, assets in Ukraine and listed in the category of commercial company shares on the London Stock Exchange (FXPO) and included in the FTSE 250 and FTSE4Good indices. The Group produces high-quality iron ore pellets, a premium product for the global steel industry that helps reduce carbon emissions and increase steel production productivity compared to other common forms of iron ore. Ferrexpo has been supplying products to the global steel industry for more than 50 years. Before Russia's full-scale invasion of Ukraine in February 2022, the Group was the third largest exporter of pellets in the world. The company has a global customer base that includes leading steel mills around the world. www.ferrexpo.com Contact Details Ferrexpo Nick Bias +44 7733 177831 n.bias@ferrexpo.com

March 27, 2025 09:45 AM Eastern Daylight Time

BX+-+168+-+2+泵吸式便携式六合一气体检测仪+厂家